

# **SHOCK**

**Pitha J.**

# Contents:

- **Definition**
- **Classification**
- **Patophysiology**
- **Diagnosis**
- **Therapy**
- **Disseminated intravascular coagulation**
- **Summary**

# DEFINITION:

- *Shock = syndrome*
- **Failure of heart pump and/or (harmonisation/coordination) of peripheral vasculature leading to critically limited blood flow – oxygenation/nutrition of peripheral tissues and to their dysfunction on the cellular level (pyruvate x lactate, mitochondria x cytoplasm).**

# Classification:

- Distributive
- Cardiogenic
- Hypovolemic
- Obstructive


+ irreversible (refractory)


# **Representation of types of shock (depends on the department):**

- 1. Distributive (66 %, from that 62 % septic/4 % anafylactic, neurogennic ...)**
- 2. Cardiogenic (16 %)**
- 3. Hypovolemic (16 %)**
- 4. Obstructive (2 %)**
- 5. Mixed (1+2+3)**


# Classification - causes:


- **Distributive** (G- sepsis, alerg. anafylaxis, spine injury, drugs in anesteziology, ...)
- **Cardiogenic** (MI, end stage heart failure ...)
- **Hypovolemic** (GIT hemorrhage, trauma, pancreatitis, ...)
- **Obstructive** (pulmonary embolism, cardiac tamponade, myxoma, dissection of asc. aorta, ...)























# **SHOCK – compensatory mechanisms**

- 1. Increased adrenergic activity/tonus – catecholamines (rcps. alfa, beta1, beta2)**
- 2. RAAS – Na retention, increased intravascular volume**
- 3. ADH/vasopresine – retention of H<sub>2</sub>O, thirst, vasoconstriction in splanchnic aa.**
- 4. Cytokines – increased activity of procoagulant/inflammatory markers**
- 5. *endorfines, encefalines, ...***

# **SHOCK – compensatory mechanisms**

**Alfa – vasoconstriction**

**Beta 1 – increased heart rate**

**Beta 2 – bronchodilation, vasodilation (striated muscles)**

**2. RAAS – ...**

**3. ADH/vasopressin – ...**

**4. *Endorfines, encefalines – pain relieve***



# **SHOCK – compensatory mechanisms**

**Priorities: to manage blood flow to central nervous system and myocardium (+ striated muscles)**

**X**

***Reduction of flow to kidneys, skin, GIT: clinical signs***

**(oliguria/anuria, cold sweated skin, hepatopathy - laboratory, ...)**

# **SHOCK – compensatory mechanisms**


**Priorities: to manage blood flow to central nervous system and myocardium (+ striated muscles)**


**X**

***Reduction of flow to kidneys, skin, GIT: clinical signs***

**(oliguria/anuria, cold sweated skin, hepatopathy - laboratory, ...)**

**Compensatory mechanisms lead to decompensations (through cytokines, ..) – with ensuing cardiodepressive effects**





# **SHOCK – irreversibility**

**Collaps of peripheral circulation, loss of function/increase of permeability of capillaries, dilation (resistence arterioles), dysfunction/afunction of life sustaining organs**

**Clinical signs: Unmeasurable blood pressure, cardiac arrest (electromechanical dissociation)**

**! Despite measurable mean blood pressure (60-70 mm Hg) during aggressive treatment (catecholamines): increase of lactate, progression of renal dysfunction, increasing acidosis,**

**Paradoxical improvement of metabolic parameters: increase of SaO<sub>2</sub> , decrease of lactate - ?**

# SHOCK – DIAGNOSIS

**History (chest pain, dyspnea, fever, .... )**

**Physical examination (vital signs – HR, BP, fever, RR, SaO<sub>2</sub>, diuresis...)**

**Laboratory**

**Other/noninvasive tests**

**Invasive tests**

# SHOCK – DIAGNOSIS

Underlying condition (ischemic heart disease, heart insufficiency, ...)

Triggers (infection, hemorrhage, arrhythmia, iatrogenic ...)

First treatment of symptoms + looking for the cause/triggers

# SHOCK – DIAGNOSIS

**Kidneys !!!: diuresis lower than 30 ml/h**

Decrease of BP (cave hypertensive patient) – changes of pulse pressure (increased x decreased cardiac output)

Tachycardia (cave previous treatment betablockers)

*Cold, sweaty skin ( not in distributive shock)*

*Impaired consciousness*

**Laboratory: increased lactate, acidosis,**

**+ spec. tests – inflammatory markers, blood count ...**



# **SHOCK - DIAGNOSIS**

**Interventional :**

**Intraarterial measurement of blood pressure, pO<sub>2</sub>, pC<sub>0</sub>2,  
pH, HCO<sub>3</sub>. ..**

**Direct measurements of central venous pressure**

**+**

**Echocardiography**

# **SHOCK - MANAGEMENT**

**1. Prevention: ATB, revascularisation**

**procedures, supplementation of fluids, ...**

**2. VIP (Ventilation, Infusions, Pump – heart**

**3. Manage the cause**

# **SHOCK - Ventilation**

**Intubate early**

**Oxygenate (40-50 % O<sub>2</sub>),**

**= decreased work of respiratory muscles,**

**improved oxygenation**

**ARDS – smaller volumes, PEEP (?), ...**

# **SHOCK - Fluid replacement (critical)**

- 1. Appropriate fluid policy (crystalloids, colloids, ...)**
- 2. Rate of replacement - 300-500 ml/30 minutes, then according to patient status**
- 3. Goal(s) – improvement of BP (70 MBP), CVP (10 cm H<sub>2</sub>O)**
- 4. Correction of overshooting (pulm. oedema, compartment sy)**

# SHOCK - Vasoactive drugs

1. Noradrenaline i.v. (0,1-2,0 ug/kg/min)
2. Angiotensin II i.v. (cave thrombosis)
3. Isoproterenol – bradycardia
4. Dopamine – alfa x beta stimulation ?
5. Vasopressine – septic shock
6. Dobutamine – does not increase BP, but improves myocardial contractility
7. Inhibitors of PDE III (amrinone, milrinone, ... )

# **SHOCK – instruments – cardiogenic shock ...**

## **Mechanical/instrumental treatment (cardiogenic shock):**

**IABC (intraarterial balloon contrapulsation)**

**ECMO (extracorp.membrane oxygenator)**

**LVAD (HM II/III – left ventr. ass. device)**

+ **Experimental:**

Inhibitors of inflammatory cytokines, ...

**CRITICAL CARE MEDICINE**

Simon R. Finfer, M.D., and Jean-Louis Vincent, M.D., Ph.D., *Editors*

# Circulatory Shock

Jean-Louis Vincent, M.D., Ph.D., and Daniel De Backer, M.D., Ph.D.

**N Engl J Med 2013;369:1726-34.**

**DOI: 10.1056/NEJMr1208943**

# **SHOCK – factors modifying prognosis**

**Age**

**Underlying diseases – ischemic heart disease,  
diabetes mellitus, ...**

**Stage of shock (reversibility) – timing of treatment**

***Critical status of microcirculation (DIC)***



# **DIC**

## **(disseminated intravascular coagulation)**

- **Syndrom accompanying another serious disease**
- **Impairment of antithrombotic endothelial function, activation of monocytes/macrophages:**

**Thrombi/fibrin deposits in microcirculation**

**Mechanical damage of thrombocytes and erythrocytes**

**Activation and consumption of coagulation factors/out of control fibrinolysis**

**(Tissue factors, f. XII – Hageman f. ...)**

# DIC

**Provoking factors:**

**Release of tissue factors (extrinsic pathway):**

**Abruption of placenta, embolization of amniotic fluid, retention of dead fetus,  
abortion in II. trimester**

**Trauma, burns**

**Malignancies**

**Direct damage of endothelium (intrinsic pathway):**

**Gram-negative sepsis, parasites, ... HUS,**

# DIC

- **Clinical manifestation:**

1. **Chronic (laboratory signs)**

2. **Acute:**

**Tissue ischemia (acrocyanosis, peripheral gangrenes, renal/liver insufficiency, ...)**

**Serious bleeding after minimal injuries - i.v., ...**

# DIC

- **Diagnosis:**

1. **Risk factors ...**

2. **Clinical manifestation – ischemia x hemorrhage**

3. **Laboratory findings: anemia (schistocytes), thrombocytopenia, prolonged PT, aPTT, decrease of fibrinogen, increase of FDP (fibrin degradation products, D-dimers, lactate (?)).**

# DIC

- **Management:**

- 1. Find and remove the cause**

- 2. Manage bleeding/ischemic complications:**

**Replacement of coagulation ff. (fresh frozen plasma, thrombocytes, coagulation ff.)**

**Heparin – chronic DIC (malignancies), combination with replacement of coagulation ff. – monitor FDP, lactate, ..**

# **CONCLUSIONS:**

- **Reveal and manage risk of shock**
- **Reveal evolving shock (diuresis!)**
- **Monitor/correct vital functions look for the cause**
- **In evolving shock apply more aggressive approach (intubation, ventilation, hydration, catecholamines).**